A phase II Randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole plus placebo in postmenopausal women with HER-positive/HER2- negative, early stage Breast Cancer.
Cristina Saura, MD, PhD (Vall d’Hebrón Institut d’Oncologia, Barcelona)
Evandro de Azambuja, MD, PhD (Jules Bordet Institute, Brussels)